Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Cancer Therapies

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Tumor Progression

Tumor Progression

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Local Recurrence and Metastasis Define Distinct Recurrence Phenotypes in Soft Tissue Sarcoma.

Cancers·2026

Same author

Value operating system: a practical framework to measure outcomes-per-cost at the episode level.

BMJ open quality·2026

Same author

A modified Delphi consensus on tenosynovial giant cell tumour and giant cell tumour of bone : a report from the Birmingham Orthopaedic Oncology Meeting (BOOM).

The bone & joint journal·2026

Same author

Complications of PI to PIII hemipelvic resections for intermediate and malignant tumours : a systematic review and meta-analysis.

Bone & joint open·2026

Same author

Treatment effect heterogeneity of radiotherapy in localized Ewing sarcoma: A secondary analysis of the EURO-E.W.I.N.G. 99 and Ewing 2008 trial.

European journal of cancer (Oxford, England : 1990)·2026

Same author

Twelve-Month Metastatic State as a Landmark-Based Prognostic Stratifier in Metastatic Sarcoma.

Cancers·2026

Search research articles

Related Experiment Video

Updated: May 2, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Recent advances in osteosarcoma.

Sander M Botter¹, Dario Neri², Bruno Fuchs¹

¹Sarcoma Center & Laboratory for Orthopedic Research, Department of Orthopedics, Balgrist University Hospital, University of Zurich, Forchstrasse 340, 8008 Zurich, Switzerland.

Current Opinion in Pharmacology

|March 18, 2014

Summary

Osteosarcoma (OS) is a rare pediatric cancer with poor survival rates. This review highlights current clinical trials and emphasizes the need for better preclinical validation and individualized treatment strategies for osteosarcoma.

More Related Videos

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Related Experiment Videos

Last Updated: May 2, 2026

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Intratibial Osteosarcoma Cell Injection to Generate Orthotopic Osteosarcoma and Lung Metastasis Mouse Models

Published on: October 28, 2021

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Establishment of Cancer Stem Cell Cultures from Human Conventional Osteosarcoma

Published on: October 14, 2016

Area of Science:

Oncology
Pediatric Oncology
Cancer Research

Background:

Osteosarcoma (OS) is a rare but aggressive bone cancer, a leading cause of cancer death in children and adolescents.
Tumor heterogeneity and low prevalence present significant challenges in developing effective treatments and improving patient survival rates.
Current therapeutic strategies often involve immune system stimulation or kinase inhibition (e.g., Src, mTOR).

Purpose of the Study:

To review current clinical trials for osteosarcoma.
To discuss novel therapeutic targets and the importance of preclinical validation.
To advocate for enhanced collaboration and individualized treatment approaches for osteosarcoma patients.

Main Methods:

Review of existing clinical trials for osteosarcoma.
Discussion of targeted therapies, including tumor-targeted TNFalpha.
Emphasis on preclinical validation and interdisciplinary cooperation.

Main Results:

Current trials focus on immunotherapy and kinase inhibitors (Src, mTOR).
Tumor-targeted TNFalpha shows potential efficacy.
Preclinical validation is crucial for advancing new therapeutic targets.

Conclusions:

Improved osteosarcoma patient survival requires intensified exchange between clinicians and basic researchers.
Individualized treatment strategies, facilitated by interdisciplinary cooperation in Sarcoma Centers, are essential for future success.
Further research into novel targets and robust preclinical validation is critical for advancing osteosarcoma therapy.